1. Home
  2. HSPO vs IKNA Comparison

HSPO vs IKNA Comparison

Compare HSPO & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HSPO
  • IKNA
  • Stock Information
  • Founded
  • HSPO 2014
  • IKNA 2016
  • Country
  • HSPO United States
  • IKNA United States
  • Employees
  • HSPO N/A
  • IKNA N/A
  • Industry
  • HSPO Blank Checks
  • IKNA Biotechnology: Pharmaceutical Preparations
  • Sector
  • HSPO Finance
  • IKNA Health Care
  • Exchange
  • HSPO Nasdaq
  • IKNA Nasdaq
  • Market Cap
  • HSPO 91.5M
  • IKNA 81.6M
  • IPO Year
  • HSPO 2022
  • IKNA 2021
  • Fundamental
  • Price
  • HSPO $11.78
  • IKNA $1.45
  • Analyst Decision
  • HSPO
  • IKNA Buy
  • Analyst Count
  • HSPO 0
  • IKNA 2
  • Target Price
  • HSPO N/A
  • IKNA $3.00
  • AVG Volume (30 Days)
  • HSPO 3.3K
  • IKNA 103.3K
  • Earning Date
  • HSPO 01-01-0001
  • IKNA 03-11-2025
  • Dividend Yield
  • HSPO N/A
  • IKNA N/A
  • EPS Growth
  • HSPO 2.63
  • IKNA N/A
  • EPS
  • HSPO 0.28
  • IKNA N/A
  • Revenue
  • HSPO N/A
  • IKNA $659,000.00
  • Revenue This Year
  • HSPO N/A
  • IKNA N/A
  • Revenue Next Year
  • HSPO N/A
  • IKNA N/A
  • P/E Ratio
  • HSPO $41.67
  • IKNA N/A
  • Revenue Growth
  • HSPO N/A
  • IKNA N/A
  • 52 Week Low
  • HSPO $10.80
  • IKNA $1.22
  • 52 Week High
  • HSPO $12.41
  • IKNA $1.94
  • Technical
  • Relative Strength Index (RSI)
  • HSPO 55.44
  • IKNA 40.55
  • Support Level
  • HSPO $11.68
  • IKNA $1.39
  • Resistance Level
  • HSPO $12.10
  • IKNA $1.53
  • Average True Range (ATR)
  • HSPO 0.14
  • IKNA 0.06
  • MACD
  • HSPO -0.00
  • IKNA -0.00
  • Stochastic Oscillator
  • HSPO 32.32
  • IKNA 37.50

About HSPO Horizon Space Acquisition I Corp.

Horizon Space Acquisition I Corp is a blank check company.

About IKNA Ikena Oncology Inc.

Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.

Share on Social Networks: